These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The feasibility of ultralow-activity 18F-FDG dynamic PET imaging in lung adenocarcinoma patients through total-body PET/CT scanner. Lv J, Yin H, Yu H, Liu G, Shi H. Ann Nucl Med; 2022 Oct; 36(10):887-896. PubMed ID: 35857172 [Abstract] [Full Text] [Related]
24. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. Matthies A, Hickeson M, Cuchiara A, Alavi A. J Nucl Med; 2002 Jul; 43(7):871-5. PubMed ID: 12097455 [Abstract] [Full Text] [Related]
25. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Kitagawa Y, Sano K, Nishizawa S, Nakamura M, Ogasawara T, Sadato N, Yonekura Y. Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411 [Abstract] [Full Text] [Related]
26. Comparison of Static and Dynamic 18F-FDG PET/CT for Quantification of Pulmonary Inflammation in Acute Lung Injury. Braune A, Hofheinz F, Bluth T, Kiss T, Wittenstein J, Scharffenberg M, Kotzerke J, Gama de Abreu M. J Nucl Med; 2019 Nov; 60(11):1629-1634. PubMed ID: 31053684 [Abstract] [Full Text] [Related]
28. Improving the Spatial Alignment in PET/CT Using Amplitude-Based Respiration-Gated PET and Respiration-Triggered CT. van der Vos CS, Grootjans W, Osborne DR, Meeuwis AP, Hamill JJ, Acuff S, de Geus-Oei LF, Visser EP. J Nucl Med; 2015 Dec; 56(12):1817-22. PubMed ID: 26383151 [Abstract] [Full Text] [Related]
29. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Vera P, Bohn P, Edet-Sanson A, Salles A, Hapdey S, Gardin I, Ménard JF, Modzelewski R, Thiberville L, Dubray B. Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487 [Abstract] [Full Text] [Related]
30. Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions. Imdahl A, Jenkner S, Brink I, Nitzsche E, Stoelben E, Moser E, Hasse J. Eur J Cardiothorac Surg; 2001 Aug; 20(2):324-9. PubMed ID: 11463551 [Abstract] [Full Text] [Related]
31. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. Cancer; 2004 Oct 15; 101(8):1776-85. PubMed ID: 15386332 [Abstract] [Full Text] [Related]
32. Value of iterative reconstruction, attenuation correction, and image fusion in the interpretation of FDG PET images with an integrated dual-head coincidence camera and X-ray-based attenuation maps. Delbeke D, Martin WH, Patton JA, Sandler MP. Radiology; 2001 Jan 15; 218(1):163-71. PubMed ID: 11152796 [Abstract] [Full Text] [Related]
35. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Minn H, Zasadny KR, Quint LE, Wahl RL. Radiology; 1995 Jul 15; 196(1):167-73. PubMed ID: 7784562 [Abstract] [Full Text] [Related]
36. Dual-head gamma camera 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in oncological patients: effects of non-uniform attenuation correction on lesion detection. Zimny M, Kaiser HJ, Cremerius U, Reinartz P, Schreckenberger M, Sabri O, Buell U. Eur J Nucl Med; 1999 Aug 15; 26(8):818-23. PubMed ID: 10436193 [Abstract] [Full Text] [Related]
37. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC). Edet-Sanson A, Dubray B, Doyeux K, Back A, Hapdey S, Modzelewski R, Bohn P, Gardin I, Vera P. Radiother Oncol; 2012 Feb 15; 102(2):251-7. PubMed ID: 21885145 [Abstract] [Full Text] [Related]
39. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT. Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Hell J Nucl Med; 2019 Feb 15; 22(1):6-9. PubMed ID: 30843003 [Abstract] [Full Text] [Related]